Lipid-lowering medication and risk of cancer. Catalogue en ligne

Titre :	Lipid-lowering medication and risk of cancer. (1999)
Auteurs :	J.H. OLSEN ; Jfjr FRAUMENI ; C. JOHANSEN ; J.K. MCLAUGHLIN ; L. MELLEMKJAER ; H.T. SORENSEN ; F.H. STEFFENSEN ; Danish Cancer Society. Institute of Cancer Epidemiology. Copenhagen. DNK
Type de document :	Article
Dans :	Journal of clinical epidemiology (vol. 52, n° 2, 1999)
Pagination :	167-169
Langues:	Anglais
Mots-clés :	Cancer ; Epidémiologie ; Homme ; Pharmacovigilance
Résumé :	[BDSP. Notice produite par INIST eR0xyUJX. Diffusion soumise à autorisation]. Low or declining levels of serum cholesterol have been associated with increased mortality from cancer. We conducted a population-based cohort study of 1882 patients from one Danish county who received lipid-lowering drugs between january 1,1991 and December 31,1994. During the follow-up period of up to 4 years, 41 cancers were observed among user of lipid-lowering drugs, with 42.9 expected, to yield an age-and sex-standardized incidence ratio of 1.0 (95% confidence interval, 0.7-1.3). Although limited hy small numbers and short follow-up period, examination by site of cancer and type of drug provided no evidence of an association. Further research is needed, however, with longer follow-up to assess more fully any potential cancer risk with these medications.

PORTAIL DOCUMENTAIRE